Skip to Content
Print Share

Leader Heartburn Relief (cimetidine) Disease Interactions

There are 4 disease interactions with Leader Heartburn Relief (cimetidine):

Major

Cimetidine (Includes Leader Heartburn Relief) ↔ liver disease

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Cimetidine is partially metabolized by the liver, and to a greater extent when administered orally than when given intravenously. Although dosage reductions are generally not necessary, therapy with cimetidine should be administered cautiously in patients with liver disease. Hepatotoxicity has been associated with cimetidine use. In addition, liver disease appears to be a risk factor for cimetidine-related central nervous system toxicity, which may include mental confusion, agitation, psychosis, depression, anxiety, hallucinations, and disorientation. These effects are usually reversible within 3 to 4 days after discontinuation of therapy.

References

  1. Taylor DC, Cresswell PR, Bartlett DC "The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog and man." Drug Metab Dispos 6 (1978): 21-30
  2. Grahnen A, Jameson S, Loof L, Tyllstrom J, Lindstrom B "Pharmacokinetics of cimetidine in advanced cirrhosis." Eur J Clin Pharmacol 26 (1984): 347-55
  3. Hashimoto F, Davis RL, Egli D "Hepatitis following treatments with famotidine and then cimetidine." Ann Pharmacother 28 (1994): 37-9
  4. del Arbol LR, Moreira V, Moreno A, et al "Bridging hepatic necrosis associated with cimetidine." Am J Gastroenterol 74 (1980): 267-9
  5. Gugler R, Muller-Liebenau B, Somogyi A "Altered disposition and availability of cimetidine in liver cirrhotic patients." Br J Clin Pharmacol 14 (1982): 421-30
  6. Bianchi Porro G, Lazzaroni M, Lodola E "Blood levels of cimetidine in patients with liver cirrhosis." Int J Clin Pharmacol Ther Toxicol 21 (1983): 374-7
  7. Van Steenbergen W, Vanstapel MJ, Desmet V, et al "Cimetidine-induced liver injury: report of three cases." J Hepatol 1 (1985): 359-68
  8. "Product Information. Tagamet (cimetidine)." SmithKline Beecham, Philadelphia, PA.
  9. Schwartz JT, Gyorkey F, Graham DY "Cimetidine hepatitis." J Clin Gastroenterol 8 (1986): 681-6
  10. Lewis JH "Hepatic effects of drugs used in the treatment of peptic ulcer disease." Am J Gastroenterol 82 (1987): 987-1003
  11. Delpre G, Kadish U, Livni E "Hepatitis following cimetidine administration." Am J Med Sci 283 (1982): 153-6
  12. Lorenzini I, Jezequel AM, Orlandi F "Cimetidine-induced hepatitis: electron microscopic observations and clinical pattern of liver injury." Dig Dis Sci 26 (1981): 275-80
  13. Boyd PT, Lepre F, Dickey JD "Chronic active hepatitis associated with cimetidine." Br Med J 298 (1989): 324-5
  14. Ziemniak JA, Bernhard H, Schentag JJ "Hepatic encephalopathy and altered cimetidine kinetics." Clin Pharmacol Ther 34 (1983): 375-82
View all 14 references
Major

H2 antagonists (Includes Leader Heartburn Relief) ↔ GI bleeding

Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Hemorrhage

Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.

Moderate

Cimetidine (Includes Leader Heartburn Relief) ↔ hemodialysis

Moderate Potential Hazard, High plausibility. Applies to: hemodialysis

Cimetidine is partially removed by hemodialysis and should be administered after dialysis.

References

  1. Larsson R, Erlanson P, Bodemar G, Norlander B, Fransson L, Strouth L "Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis." Eur J Clin Pharmacol 21 (1982): 325-30
  2. Bjaeldager PA, Jensen JB, Nielsen LP, Larsen NE, Hvidberg EF "Pharmacokinetics of cimetidine in patients undergoing hemodialysis." Nephron 34 (1983): 159-63
  3. "Product Information. Tagamet (cimetidine)." SmithKline Beecham, Philadelphia, PA.
  4. Pizzella KM, Moore MC, Schultz RW, Walshe J, Schentag JJ "Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion." Ther Drug Monit 2 (1980): 273-81
View all 4 references
Moderate

Cimetidine (Includes Leader Heartburn Relief) ↔ renal dysfunction

Moderate Potential Hazard, High plausibility. Applies to: Renal Dysfunction

Cimetidine and its metabolites are primarily eliminated by the kidney. The daily dosage should initially be reduced in patients with moderate to severe renal impairment (CrCl < 50 mL/min). If necessary, the daily dosage may be increased with caution. Renal dysfunction also appears to be a risk factor for cimetidine-related central nervous system toxicity, which may include mental confusion, agitation, psychosis, depression, anxiety, hallucinations, and disorientation. These effects are generally reversible within 3 to 4 days after discontinuation of therapy.

References

  1. Larsson R, Bodemar G, Kagedal B "The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function." Acta Med Scand 205 (1979): 87-9
  2. Seidelin R "Cimetidine and renal failure." Postgrad Med J 56 (1980): 440-1
  3. "Product Information. Tagamet (cimetidine)." SmithKline Beecham, Philadelphia, PA.
  4. Larsson R, Norlander B, Bodemar G, Walan A "Steady-state kinetics and dosage requirements of cimetidine in renal failure." Clin Pharmacokinet 6 (1981): 316-25
  5. Guay DR, Matzke GR, Bockbrader HN, Dancik J "Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function." Clin Pharm 2 (1983): 157-62
  6. Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994): 393-408
  7. Larsson R, Erlanson P, Bodemar G, Walan A, Bertler A, Fransson L, Norlander B "The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function." Br J Clin Pharmacol 13 (1982): 163-70
View all 7 references

Leader Heartburn Relief (cimetidine) drug interactions

There are 844 drug interactions with Leader Heartburn Relief (cimetidine)

Leader Heartburn Relief (cimetidine) alcohol/food interactions

There are 3 alcohol/food interactions with Leader Heartburn Relief (cimetidine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide